Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide
Vivos Therapeutics (NASDAQ: VVOS) announced significant expansions and achievements in its strategic alliance with Rebis Health Holdings. The company is extending its FDA-cleared Vivos CARE treatment for OSA into two additional Denver market facilities and plans nationwide expansion through sleep center affiliations and acquisitions.
Initial data shows a 64% acceptance rate for Vivos treatment, with patients preferring it nearly 2:1 over CPAP. The company reports average per case revenue of over $4,700 with gross margins around 70% before profit sharing with Rebis. The new business model shows potential for up to four times greater profit per case compared to their previous distribution model.
The expansion includes new locations in Highlands Ranch and Westminster, expected to be operational by April. Vivos is exploring partnerships with over 2,500 accredited sleep medicine groups nationwide, aiming to accelerate revenue growth and achieve cash flow-positive operations.
Vivos Therapeutics (NASDAQ: VVOS) ha annunciato importanti espansioni e risultati nella sua alleanza strategica con Rebis Health Holdings. L'azienda sta estendendo il trattamento Vivos CARE, approvato dalla FDA per l'OSA, in due nuovi centri a Denver e prevede un'espansione a livello nazionale attraverso affiliazioni e acquisizioni di centri del sonno.
I dati iniziali mostrano un tasso di accettazione del 64% per il trattamento Vivos, con i pazienti che lo preferiscono quasi 2:1 rispetto al CPAP. L'azienda riporta un ricavo medio per caso di oltre $4.700 con margini lordi intorno al 70% prima della condivisione dei profitti con Rebis. Il nuovo modello di business mostra un potenziale di profitto fino a quattro volte maggiore per caso rispetto al loro precedente modello di distribuzione.
L'espansione include nuove sedi a Highlands Ranch e Westminster, previste per essere operative entro aprile. Vivos sta esplorando partnership con oltre 2.500 gruppi di medicina del sonno accreditati a livello nazionale, mirando ad accelerare la crescita dei ricavi e raggiungere operazioni positive in termini di flusso di cassa.
Vivos Therapeutics (NASDAQ: VVOS) anunció importantes expansiones y logros en su alianza estratégica con Rebis Health Holdings. La compañía está ampliando su tratamiento Vivos CARE, aprobado por la FDA para la OSA, a dos instalaciones adicionales en el mercado de Denver y planea una expansión a nivel nacional a través de afiliaciones y adquisiciones de centros de sueño.
Los datos iniciales muestran una tasa de aceptación del 64% para el tratamiento Vivos, con pacientes que lo prefieren casi 2:1 sobre el CPAP. La compañía reporta un ingreso promedio por caso de más de $4,700 con márgenes brutos alrededor del 70% antes de compartir ganancias con Rebis. El nuevo modelo de negocio muestra un potencial de hasta cuatro veces más de ganancias por caso en comparación con su modelo de distribución anterior.
La expansión incluye nuevas ubicaciones en Highlands Ranch y Westminster, que se espera que estén operativas para abril. Vivos está explorando asociaciones con más de 2,500 grupos de medicina del sueño acreditados a nivel nacional, con el objetivo de acelerar el crecimiento de ingresos y lograr operaciones con flujo de caja positivo.
비보스 테라퓨틱스 (NASDAQ: VVOS)는 레비스 헬스 홀딩스와의 전략적 제휴에서 중요한 확장과 성과를 발표했습니다. 이 회사는 FDA에서 승인된 OSA 치료법인 비보스 CARE를 덴버의 두 개 추가 시설로 확장하고, 수면 센터 제휴 및 인수를 통해 전국적으로 확장할 계획입니다.
초기 데이터에 따르면 비보스 치료의 수용률이 64%에 달하며, 환자들은 CPAP보다 거의 2:1의 비율로 비보스 치료를 선호하고 있습니다. 이 회사는 레비스와의 이익 분배 이전에 사례당 평균 수익이 $4,700 이상이라고 보고하고 있으며, 총 마진은 약 70%입니다. 새로운 비즈니스 모델은 이전 유통 모델에 비해 사례당 최대 4배 더 높은 이익 잠재력을 보여줍니다.
확장에는 하이랜즈 랜치와 웨스트민스터의 새로운 위치가 포함되며, 4월까지 운영될 것으로 예상됩니다. 비보스는 전국적으로 2,500개 이상의 인증된 수면 의학 그룹과의 파트너십을 탐색하고 있으며, 수익 성장을 가속화하고 현금 흐름이 긍정적인 운영을 달성하는 것을 목표로 하고 있습니다.
Vivos Therapeutics (NASDAQ: VVOS) a annoncé d'importantes expansions et réalisations dans son alliance stratégique avec Rebis Health Holdings. L'entreprise étend son traitement Vivos CARE, approuvé par la FDA pour l'OSA, à deux installations supplémentaires sur le marché de Denver et prévoit une expansion nationale grâce à des affiliations et des acquisitions de centres de sommeil.
Les données initiales montrent un taux d'acceptation de 64% pour le traitement Vivos, les patients le préférant presque 2:1 par rapport au CPAP. L'entreprise rapporte un revenu moyen par cas de plus de 4 700 $ avec des marges brutes d'environ 70 % avant le partage des bénéfices avec Rebis. Le nouveau modèle commercial montre un potentiel de bénéfice jusqu'à quatre fois supérieur par cas par rapport à leur précédent modèle de distribution.
L'expansion comprend de nouveaux sites à Highlands Ranch et Westminster, qui devraient être opérationnels d'ici avril. Vivos explore des partenariats avec plus de 2 500 groupes de médecine du sommeil accrédités à l'échelle nationale, visant à accélérer la croissance des revenus et à atteindre des opérations positives en termes de flux de trésorerie.
Vivos Therapeutics (NASDAQ: VVOS) hat bedeutende Erweiterungen und Erfolge in seiner strategischen Allianz mit Rebis Health Holdings angekündigt. Das Unternehmen erweitert seine von der FDA genehmigte Vivos CARE-Behandlung für OSA auf zwei zusätzliche Einrichtungen im Markt Denver und plant eine landesweite Expansion durch Partnerschaften und Übernahmen von Schlafzentren.
Erste Daten zeigen eine Akzeptanzrate von 64% für die Vivos-Behandlung, wobei Patienten diese fast 2:1 gegenüber CPAP bevorzugen. Das Unternehmen berichtet von einem durchschnittlichen Umsatz pro Fall von über 4.700 $ mit Bruttomargen von rund 70% vor der Gewinnbeteiligung mit Rebis. Das neue Geschäftsmodell zeigt das Potenzial für bis zu viermal höhere Gewinne pro Fall im Vergleich zu ihrem vorherigen Vertriebsmodell.
Die Expansion umfasst neue Standorte in Highlands Ranch und Westminster, die voraussichtlich bis April betriebsbereit sein werden. Vivos untersucht Partnerschaften mit über 2.500 akkreditierten Schlafmedizin-Gruppen im ganzen Land, um das Umsatzwachstum zu beschleunigen und einen positiven Cashflow zu erreichen.
- 64% treatment acceptance rate, showing strong patient preference over CPAP
- Average revenue per case exceeding $4,700 with 70% gross margins
- Potential for 4x greater profit per case compared to previous model
- Expansion into two additional Denver market facilities
- Less than 0.1% retreatment rate among 60,000 treated patients since 2010
- Current cash burn situation needs improvement
- Revenue growth expected to ramp over time, indicating delayed financial impact
- patient interactions (less than 400) in initial data
Insights
The strategic transformation of Vivos Therapeutics represents a significant pivot in their business model, with three key developments that warrant investor attention:
Revenue Model Enhancement: The new alliance model demonstrates superior unit economics, with per-case revenue of
Market Validation and Expansion: The
Strategic Growth Potential: The company's pursuit of partnerships or acquisitions among 2,500+ accredited sleep centers nationwide presents a clear growth pathway. This expansion strategy could potentially transform Vivos from a medical device manufacturer into a vertically integrated healthcare services provider, significantly expanding their market opportunity and revenue potential.
However, investors should consider several critical factors: The reported metrics are based on patient interactions (fewer than 400), making it premature to extrapolate long-term success rates. The expansion strategy will require significant operational execution capability and potentially additional capital. The company's ability to maintain quality control and consistent patient outcomes across an expanded network will be important for sustainable growth.
Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 over CPAP
Vivos seeking additional alliances or acquisitions of sleep medicine practices to fuel national expansion objectives
LITTLETON, Colo., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in novel, non-invasive obstructive sleep apnea (OSA) treatments, today announced several significant milestone achievements in its efforts to extend its FDA cleared Vivos CARE treatment for OSA to as many patients as possible.
Vivos also announced expansion of its strategic marketing and distribution alliance with Rebis Health Holdings (Rebis Health) launched last June into two additional facilities in the greater Denver market, along with plans to extend its marketing and distribution model throughout the United States with potential additional sleep center affiliations and acquisitions.
Initial Alliance Data Shows OSA Patients Prefer Vivos Treatment 2:1 Over CPAP
Data gathered by Vivos and Rebis Health over the initial months of their strategic alliance shows an overall Vivos treatment case acceptance rate of
During the initial months of the alliance, existing Rebis Health OSA patients, some of which had previously tried CPAP and indicated they were either dissatisfied or had ceased CPAP use, and other newly diagnosed OSA patients, were approached and educated about their OSA treatment options, including Vivos CARE as a potentially rehabilitative treatment over an approximate one year time frame.
Vivos CARE treatment offers several key advantages over CPAP, a cumbersome 40-year-old technology that covers the face and must be used nightly over a patient’s lifetime to be effective. Studies have shown that Vivos CARE devices have the ability to rehabilitate and enhance airway functionality, with initial therapeutic benefits often achieved relatively quickly (in days or weeks) and final clinical results typically achieved in as little as 12 months. Importantly, Vivos CARE treatment has been shown to reduce or even eliminate OSA symptoms as measured by the Apnea Hypopnea Index (AHI). Unlike CPAP, which only manages symptoms, Vivos CARE targets and corrects the structural issues behind most OSA cases. After completing their Vivos CARE treatment, many patients may not require further intervention, though individual experiences can vary, and long-term results may differ. Of the nearly 60,000 patients treated since 2010, fewer than approximately
Rebis Health has over 90,000 legacy OSA patients and currently sees approximately 1,200 potential new OSA patients each month. After months of preparation and training during the second half of 2024, and with somewhat limited (less than 400) patient interactions, Rebis Health medical providers are now educating substantially all their OSA patients on Vivos treatment as an alternative to CPAP. Through the strategic alliance, Vivos and Rebis Health are seeking to provide each patient with the full range of treatment options, including Vivos CARE devices.
Vivos Sees Potential for Increased Revenue and Profit per Patient Via Strategic Alliance Model Amid Growing Patient Demand
The second milestone achievement is average per case revenue of over
“We’ve worked diligently over the first months of our alliance with Rebis Health to refine and optimize it as well as gain further validation of the exciting potential for Vivos as we roll out this new model on a national scale,” said Kirk Huntsman, Chairman and CEO of Vivos. “The realization of these initial two key milestones regarding patient preferences and improved economics for Vivos is validating of our efforts to date and made our decision to expand from our initial location with Rebis into two additional locations in the greater Denver area a no-brainer. Our achievements with Rebis have been in line with our expectations, and we see a lot of room for further improvement in terms of revenue growth and margin expansion as patients continue to accept Vivos treatment options. Moreover, these initial positive developments are leading us to accelerate our exploration of additional strategic alliances or outright acquisitions of sleep centers through which we can market our products and services. We view this new business model as a critical inflection point in the history of Vivos and for OSA treatment overall. No longer will patients just blindly accept CPAP as their life sentence for being diagnosed with OSA. Patients now know they have real choices and very good alternatives.”
The new Colorado locations for the strategic alliance are located in Highlands Ranch and Westminster, both suburbs of Denver. Both locations are expected to be fully staffed and operational by April. Eventually, Vivos and Rebis Health aim to have locations and providers serving all of Colorado.
Vivos is currently exploring alliances or acquisitions of some of the more than 2,500 accredited sleep medicine and testing groups in major United States cities. If these materialize, they are expected to accelerate and enhance Vivos’ top-line revenue growth while significantly lowering or ending Vivos’ current cash burn and generating cash flow-positive operations in the future.
About VIVOS THERAPEUTICS
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA). Vivos’ devices are FDA-cleared for adult patients diagnosed with all severity levels of OSA and the flagship device, the Vivos DNA is FDA cleared to treat children ages 6 to 17 who are diagnosed with snoring and or moderate or severe OSA and need orthodontic treatment. Vivos’ groundbreaking CARE devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the Vivos DNA is the first oral device to receive a 510(k) clearance for treating moderate to severe OSA in children.
Obstructive sleep apnea (OSA) affects over 1 billion people worldwide, yet
Vivos Therapeutics, founded in 2016 and based in Littleton, CO, is changing this. Through innovative technology, education, and partnerships with dentists, functional medicine doctors, and sleep specialists, Vivos is empowering healthcare providers to more thoroughly address the complex needs of patients.
The Vivos Method offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life. For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”, “aim” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to the actual future impact of the corporate achievements described herein on Vivos’ future revenues and results of operations and the anticipated benefits and potential expansion of Vivos’ marketing and distribution model as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Readers are cautioned that actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financing on reasonable terms when needed, if at all or maintain its Nasdaq listing and (v) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629
jotopr.com
FAQ
What is the acceptance rate for Vivos CARE treatment compared to CPAP?
What are the financial metrics for VVOS's new strategic alliance model?
When will VVOS's new Colorado locations become operational?
What is the retreatment rate for Vivos CARE patients?
How many sleep medicine centers is VVOS targeting for potential expansion?
